Cambridge life science trio to storm Wall Street in $1/4 billion NASDAQ IPO surge
Cambridge life science pioneer Bicycle Therapeutics is targeting an $86 million IPO on the US technology market NASDAQ – leading an unprecedented charge to Wall Street for life science companies in the UK’s leading life science cluster.
Business Weekly has been told by an informed source that Cambridge duo F-star and Kymab – both in the antibodies arena – intend to follow Bicycle to NASDAQ floats for roughly similar valuations.
For some while it has been a question which of the supercharged trio, all based on the Babraham Research Campus, would break cover first.
Bicycle is developing a new class of small, chemically synthesised medicines – called Bicycles – targeting cancers and other diseases. The company’s platform is based on the monoclonal antibodies science conducted by Sir Greg Winter, recently honoured as a Nobel Prize winner, and Professor Christian Heinis. The business is headed by ex-Pfizer research leader Kevin Lee.
Bicycle has research collaborations with AstraZeneca in respiratory, cardiovascular and metabolic disease, Bioverativ in non-malignant haematology indications, including haemophilia, and with Oxurion in ophthalmology.
Cambridge Innovation Capital, a patient capital fund principally backing hi-tech and biotech companies spinning out of Cambridge University, stands to receive a bumper dividend from a Bicycle exit.
Bicycle has not made any official comment on the NASDAQ IPO or issued any publicity but has pointed Business Weekly to sources confirming the move.
An influential inside-track life science entrepreneur told Business Weekly that F-star and Kymab are tipped to follow the lucrative trail to New York.
F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as 2-in-1 drugs.
Kymab rapidly develops broad diversity, high-quality human antibodies for treating challenging diseases.
Bicycle’s NASDAQ sortie would be the first life science IPO either side of the Atlantic so far in 2019. Cambridge already has cannabis-based medicines trailblazer GW Pharmaceuticals thriving and raising mega-money on NASDAQ but this latest move would be unprecedented for the UK, let alone the Cambridge, biotech community, in terms of numbers and potential payback.